Synapse - Genitourinary Oncology Service

Results (5687)

A phase I dose-escalation study of the HIF-2 alpha inhibitor DFF332 in patients with advanced clear-cell renal cell carcinoma

Journal Article

Pal, S. K.; Bernard-Tessier, A.; Grell, P.; Gao, X.; Kotecha, R. R.; Picus, J.; de Braud, F.; Takahashi, S.; Wong, A.; Suárez, C.; more...
Clinical Cancer Research (2025)

Fulltext@MSK | Save

Recommended clinical context and patient context data elements for liquid biopsy data submitted to data repositories and data commons

Guidelines

Grossman, R. L.; Vinson, J.; Bain, E.; Bisselou, K.; Chandan, S.; Compton, C.; Hu, J.; Johann, D. J.; Jones, F.; Jones, G.; more...
CTS-Clinical and Translational Science (2025)

Fulltext@MSK | Save

Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post-immune-oncology and vascular endothelial growth factor receptor targeted therapies

Journal Article

Shah, N. J.; Sura, S.; Shinde, R.; Shi, J.; Bupathi, M.; Vickery, D.; Motzer, R. J.
Cancers (2025)

Fulltext@MSK | Save

High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes

Journal Article

Sharifi, M. N.; Sperger, J. M.; Taylor, A. K.; Tippins, K. E.; Reese, S. R.; Carreno, V.; Kaufmann, K. R.; Chang, A. H.; Nunamaker, L. A.; Linebarger, C.; more...
Cancer Discovery (2025)

Fulltext@MSK | Save

INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC)

Meeting Abstract

Motzer, R. J.; Braun, D. A.; Powles, T.; Gurney, H.; Fong, L.; George, D. J.; Haas, N. B.; McDermott, D. F.; Shuch, B. M.; Meehan, R.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Meeting Abstract

Mak, B.; Tran, B.; Thomas, H.; Pashankar, F. D.; Hansen, A. R.; Feldman, D. R.; Huddart, R. A.; Wheater, M.; Dunwoodie, E.; Mazhar, D.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors

Meeting Abstract

Gao, X.; Patnaik, A.; Lakhani, N. J.; Call, J. A.; Galsky, M. D.; Garmezy, B.; Wei, A. Z.; Carter, L.; Powles, T.; Siefker-Radtke, A. O.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301)

Meeting Abstract

Hansen, A. R.; Zhang, A. Y.; Boni, V.; Mantia, C.; Yu, E. Y.; Weickhardt, A. J.; Robert, M.; Gupta, S.; Morales-Barrera, R.; Hoimes, C. J.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer

Meeting Abstract

Morris, M. J.; Kiess, A. P.; Nordquist, L.; Gupta, S.; George, D. J.; Messmann, R. A.; Kantoff, P. W.; Nauseef, J. T.; Bander, N. H.; Antonarakis, E. S.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)

Meeting Abstract

Chen, Y. W.; Liu, L.; Cheng, Y.; Araneta, A.; Castano, N.; Gomez, J.; Ajmera, A.; Ye, H.; Runcie, K.; McHugh, D. J.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save